Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BiStat Biomedical Co., Ltd. 〉Methylation-Specific-PCR (MSP)

Methylation-Specific-PCR (MSP)

Methylation-Specific-PCR (MSP)

iStat holds several patents and intellectual properties that on DNA methylation of cancer biomarkers.

Request for Collaboration
Overview
•iStat's technology platform, Methylation-Specific-PCR (MSP), is a proprietary DNA-based technology that detects tumor-specific gene methylation with high precision and accuracy.
•Aberrant DNA methylation has known to be associated with human cancers through epigenetic gene silencing of tumor suppressor and DNA repair genes. iStat's MSP provides optimal solutions for physicians in cancer diagnosis and therapy monitoring.
•iStat holds several patents and intellectual properties on the MSP technology which targets a broad portfolio of biomarkers designating for different products.

Methylation Specific PCR (MSP)
Methylation-specific PCR can rapidly assess the methylation status of CpG sites within a CpG island. An MSP assay entails initial modification of DNA by sodium bisulfite, converting all unmethylated cytosines to uracil. Subsequently, modificated DNA amplified with primers specific for methylated DNA. The use of a Real Time Quantitative MSP enables highly accurate discrimination between positive and negative findings.
Features of iStat's MSP:
•High sensitivity - sensitively detects low levels methylated biomarkers.
•High specificity - targets specific tumor markers.
•Early detection - detects earlier stage precancerous lesions
•User friendly kit design and simplified assay procedures - shortens turn around time
Application
Assay Process
The MSP assays are performed on DNA isolated from patient samples. The extracted DNA is chemically treated to convert the unmethylated cytosines to uracil and subsequent PCR amplification with methylation specific primers allows for the quantitative measurement of methylated alleles. These results are subsequently used to report a clinically meaningful result to treating physicians.
Patent Portfolio
License-in
  1. License-in : 
    • IP Titles : CANCER SCREENING METHOD I
      • Genes : PAX1、 SOX1、LMX1A、NKX6.1
      • Country : TW , MY, US, CN, HK
      • Related-cancer disease : Cervical cancer, liver cancer
    • IP Titles : CANCER SCREENING METHOD II
      • Genes : PTPRR、ZNF582、PDE8B、DBC1
      • Country : TW, CN, NZ, US, SG, AU, KR, PH, HK, CA, JP, ID, MY, IL, EU, IN, VN, BR
      • Related-cancer disease : Cervical cancer
  2. Reagent patent :
    • IP Titles : TEST COMPOSITION FOR SCREENING CANCERS
      • Genes : PAX1、ZNF582、SOX1、NKX6-1
      • Country : TW, CN, HK, JP, KR, ID, IN, MY, SG, PH, VN, TH, AU, US, BR, CA, EPC (EU)
      • Related-cancer disease : Cervical cancer, oral cancer,
        head and neck cancer, esophageal cancer, colorectal cancer, liver cancer, ovarian cancer, breast cancer,tongue cancer, lung cancer, skin cancer
People who like this also like
  • Chemistry Manufacturing and Controls (CMC)Chemistry Manufacturing and Controls (CMC)
  • PHDC-02PHDC-02
  • TLC178TLC178
  • Multi-day Transdermal Drug Delivery (MTDD)Multi-day Transdermal Drug Delivery (MTDD)
  • BioScan ControlBioScan Control
  • HPAPI manufacturingHPAPI manufacturing
  • PipelinePipeline
  • ON101- New drug for diabetic foot ulcer healingON101- New drug for diabetic foot ulcer healing
  • Lab FacilityLab Facility
  • Breast Image Matching Method and Image Processing ApparatusBreast Image Matching Method and Image Processing Apparatus